Abstract
Immunoglobulin E (IgE) plays a central role in the development of allergic diseases. In sensitized individuals, IgE antibodies bind to receptors on mast cell and basophil surfaces, releasing preformed and newly generated mediators that initiate an immunologic cascade and inflammatory symptoms. Omalizumab (Xolair®) is a humanized monoclonal antibody designed to bind specifically to IgE. It was approved by the United States Food and Drug Administration in 2003 for the treatment of patients with moderate-to-severe persistent asthma that is inadequately controlled with inhaled corticosteroids (ICS) and who have a positive skin test or in vitro reactivity to a perennial aeroallergen. In clinical trials in such patients, omalizumab reduced the incidence of asthma exacerbations, severe exacerbations, the use of rescue medication, and improved both symptoms and quality of life (QOL).
Keywords: IgE, allergy, asthma, rhinitis, omalizumab
Current Pharmaceutical Design
Title: IgE, Allergic Diseases, and Omalizumab
Volume: 12 Issue: 30
Author(s): L. M. DuBuske
Affiliation:
Keywords: IgE, allergy, asthma, rhinitis, omalizumab
Abstract: Immunoglobulin E (IgE) plays a central role in the development of allergic diseases. In sensitized individuals, IgE antibodies bind to receptors on mast cell and basophil surfaces, releasing preformed and newly generated mediators that initiate an immunologic cascade and inflammatory symptoms. Omalizumab (Xolair®) is a humanized monoclonal antibody designed to bind specifically to IgE. It was approved by the United States Food and Drug Administration in 2003 for the treatment of patients with moderate-to-severe persistent asthma that is inadequately controlled with inhaled corticosteroids (ICS) and who have a positive skin test or in vitro reactivity to a perennial aeroallergen. In clinical trials in such patients, omalizumab reduced the incidence of asthma exacerbations, severe exacerbations, the use of rescue medication, and improved both symptoms and quality of life (QOL).
Export Options
About this article
Cite this article as:
DuBuske L. M., IgE, Allergic Diseases, and Omalizumab, Current Pharmaceutical Design 2006; 12 (30) . https://dx.doi.org/10.2174/138161206778559641
DOI https://dx.doi.org/10.2174/138161206778559641 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hypersensitivity Reactions to Ophthalmic Products
Current Pharmaceutical Design Patent Selections
Recent Patents on Anti-Infective Drug Discovery Stress Hormone-Mediated DNA Damage Response -- Implications for Cellular Senescence and Tumour Progression
Current Drug Targets Heat Shock Paradox and a New Role of Heat Shock Proteins and their Receptors as Anti-Inflammation Targets
Inflammation & Allergy - Drug Targets (Discontinued) The Toll-Like Receptor Radical Cycle Pathway: A New Drug Target in Immune-Related Chronic Fatigue
CNS & Neurological Disorders - Drug Targets Chemokine Receptors as Targets for Cancer Therapy
Current Pharmaceutical Design Copper as a Biocidal Tool
Current Medicinal Chemistry Cereal Exposures in the Infant Diet and Risk of Diabetes Autoimmunity in Children
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Histamine H4 Receptor: A Novel Target for Inflammation Therapy
Mini-Reviews in Medicinal Chemistry Design, Synthesis and Biological Evaluation of 4, 6-Coumarin Derivatives as Anti- Cancer and Apoptosis-Inducing Agents
Anti-Cancer Agents in Medicinal Chemistry Kinase Inhibitors with Redox and Anti-inflammatory Activities
Current Topics in Medicinal Chemistry Biodiversity and Chemodiversity: Future Perspectives in Bioprospecting
Current Drug Targets Beta-Blockers as First Line Treatment of Hypertension: A Proponents View
Current Hypertension Reviews Colloidal Carriers for Ophthalmic Drug Delivery
Current Drug Targets Fibrate-Associated Adverse Effects Beyond Muscle and Liver Toxicity
Current Pharmaceutical Design Medication Conveyance Through Nose: Factors Affecting and Novel Applications
Drug Delivery Letters Use of Toll-Like Receptor 3 Agonists Against Respiratory Viral Infections
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Bronchial Thermoplasty: Burn to Cure?
Current Respiratory Medicine Reviews Single Nucleotide Polymorphisms (SNPs): History, Biotechnological Outlook and Practical Applications
Current Pharmacogenomics Pharmacotherapy & Surgical Interventions Available for Obesity Management and Importance of Pancreatic Lipase Inhibitory Phytomolecules as Safer Anti-Obesity Therapeutics
Mini-Reviews in Medicinal Chemistry